cyrilzakka/clinical-trials huggingface dataset:
Short Pulse and Q-switched ND-YAG Laser With Topical Carbon Versus Fractional CO2 Laser for Enlarged Facial Pores

Facial pores are visible topographic features of the skin that reflect openings of pilosebaceous follicles, that may be enlarged causing distress to some individuals. Many patients desire treatment for this condition, which can be an early sign of skin aging. Therapeutic modalities include intense pulsed light, radiofrequency, dermabrasion, oral and topical retinoids, as well as chemical peeling. Lasers, as fractional CO2, short pulse and Q-switched Nd-YAG, can potentially be used in treatment of wide pores.

This study aims at the assessment and comparison of therapy with short pulsed and Q-switched Nd-YAG laser plus topical carbon with fractional CO2 laser in the management of wide facial pores.

topical carbon cream will be applied to one side of the face in patients with wide facial pores, followed by 2 passes of short pulse 1064 ND:YAG laser, then one pass of Q-switched ND-YAG laser.

fractional CO2 laser will be performed to the other half of the face. the patients will receive 2 treatment sessions

Eligibility Criteria:
Inclusion Criteria:

* Participants who are more than 18 years old with the large facial pores and are aware of their problem and seeking treatment

Exclusion Criteria:

* • Previous laser therapy, chemical peeling, microdermabrasion or cosmetic procedure for the face.

  * Patients with any contraindication to laser therapy such as photosensitive diseases, skin malignancies, patients on oral retinoids.
  * Keloid-forming tendency.
  * Local or systemic treatment for skin pores in the previous 3 months
  * Connective tissue disease or the use of immunosuppressive medications.
  * Pregnancy.
  * Present or past history of herpes labialis.
Seerlinq: Non-invasive LVFP Monitoring in HF

Left ventricular filling pressure (LVFP) monitoring has been associated with improved quality of life, survival and reduced hospitalization rates. However, current LVFP monitoring methods are invasive, costly, and require long-term antithrombotic therapy.

The purpose of this study is to validate Seerlinq HeartCore, a novel CE-certified, non-invasive system that enables remote LVFP monitoring using photoplethysmography (PPG) and machine learning-based signal analysis.

Heart failure (HF) affects approximately 1-2% of the adult population in developed countries, with prevalence exceeding 10% among individuals older than 70 years. Despite advancements in diagnostics and treatment guided by evidence-based medicine, HF remains associated with high morbidity and mortality; up to 17% of patients die and up to 44% require hospitalization within 12 months.

Monitoring of left ventricular filling pressure (LVFP) has been shown to improve survival, quality of life, and reduce hospitalization rates in patients with HF. However, existing methods for LVFP assessment are invasive, costly, and require long-term antithrombotic therapy, limiting their widespread application.

The purpose of this study is to validate HeartCore, a novel CE-certified, non-invasive system that enables remote LVFP monitoring using photoplethysmography (PPG) combined with machine learning-based signal analysis.

This will be a prospective, multicenter study enrolling three patient cohorts:

RHC cohort, ECHO cohort, and RPM cohort. Participants will undergo 120-second PPG recordings in both upright and supine positions using a standard pulse oximeter connected to a smartphone. The PPG signals will be transmitted to a secure server and processed by the HeartCore algorithm to estimate LVFP, expressed as the diastolic reserve index (DRI), where a higher DRI indicates lower LVFP.

The primary outcomes of the study will be:

* The discrimination performance of the PPG-based HeartCore system for detecting elevated LVFP in the RHC and ECHO cohorts, measured by receiver operating characteristic area under the curve (ROC AUC), sensitivity, and specificity.
* The change in DRI following furosemide up-titration in the RPM cohort.

The secondary outcome will be:

• The correlation between DRI and pulmonary capillary wedge pressure (PCWP) in the RHC cohort.

This study aims to demonstrate that a non-invasive, widely available, and scalable PPG-based system can provide reliable assessment of LVFP in HF patients, potentially improving the management and outcomes of this population.

Eligibility Criteria:
Inclusion Criteria:

* Males and females aged ≥ 18 years
* Able to understand, and willing to provide written ICF
* Stated willingness to comply with all study procedures
* Healthy volunteer

Exclusion Criteria:

* Pregnancy or female participant lactating
* Other possible unforeseen medical conditions that the investigator deems unsafe for study participation
Sixteen Years Trends in Reported Undernutrition in Switzerland

To assess 16-year trends in undernutrition reporting and management in Switzerland

Analysis of data from the Swiss hospital discharge databases between 1998 and 2014. The database was provided by the Swiss federal office of statistics (http://www.bfs.admin.ch); it covers 98% of public and private hospitals within Switzerland and includes all stays for each hospital.

Eligibility Criteria:
Inclusion Criteria:

* adult patients (aged ≥20 years), length of hospital stay \>1 day, not having any ICD-10 codes related to pregnancy, childbirth and puerperium (i.e. ICD-10 codes beginning with letter "O") as main diagnosis, and having complete demographic data and information on main diagnosis and mortality

Exclusion Criteria:

-
C3 Laminectomy With Cervical Laminoplasty

1. Background In cervical stenosis, cervical laminoplasty from the third to sixth cervical vertebrae is widely used. However, the muscles attached to the C2, which play an important role in the movement of our neck, are frequently damaged during the C3 laminoplasty. In contrast, cervical spine surgery through the removal of the C3 is thought to give less damage to the muscles attached to the C2.
2. Purpose The aim of this study was to compare the prospective randomized comparison of these two surgical methods.
3. Hypothesis There is no difference in the cervical length and overall cervical angle between 1 month, 3 months, 6 months, and 12 months postoperatively between C3 laminectomy with C4-6 laminoplasty and C3-6 laminoplasty.

Surgery is performed under general anesthesia as before, followed by posterior cervical incision. In one group, the cervical spine of the C3 is removed using a drill and punch and C4-6 laminoplasty will be performed. In the other group, C3-6 laminoiplasty will be performed. Postoperative suturing and subject management are the same as existing patient care policies. Follow-up is performed at 1 month, 3 months, 6 months, 12 months, and 1 year after surgery at the outpatient clinic and x-ray is taken at each outpatient follow-up. The degree of the neck pain is measured using NDI and VAS for each outpatient f/u.

Eligibility Criteria:
Inclusion Criteria:

* cervical stenosis

Exclusion Criteria:

* metastatic tumor
* fracture
* previous cervical spine surgery (posterior approach)
Study to Test Software Algorithm for Insulin Therapy and New Glucose Sensor

To investigate the performance of a software-algorithm based insulin therapy to control blood glucose in Type 1 diabetic patients.


Eligibility Criteria:
Inclusion Criteria:

* Male or female aged 18 to 75 years (both inclusive)
* Informed consent obtained after being advised of the nature of the study
* The subject has Type 1 diabetes (as defined by WHO) for at least 24 months
* The subject's HbA1c \<= 10%
* Body Mass Index (BMI) \<= 35 kg/m2
* The subject is treated with continuous subcutaneous insulin infusion for at least 3 month

Exclusion Criteria:

* Subject is actively enrolled in another clinical trial or took part in a study within 30 days
* Experienced recurrent severe hypoglycaemic unawareness
* Total daily insulin dose \>= 1.4 IU/kg
* Subject is using a medication that significantly impacts glucose metabolism (oral or topical steroids) except if stable for at least the last three months and expected to remain stable for the study duration
* Allergy against insulin Lispro
* A history of drug or alcohol dependence
* Any other significant concomitant disease such as endocrine, cardiac, neurological, malignant, other pancreatic disease or uncontrolled hypertension as judged by the investigator
* Uncontrolled hypertension with resting blood pressure over 140/90 mmHg
* Patient is pregnant, or breast feeding during the period of the study
* Patient donated blood in the last 3 months
Complications in Singleton Pregnancies Following Previous Cesarean Myomectomy

The present study aims to investigate whether there is a difference in short- and long-term complications in patients undergoing cesarean myomectomy (endometrial or serosal myomectomy) during cesarean section.

Myomectomy is frequently performed during cesarean section. Infertility, myoma recurrence, adhesions , uterine rupture (complete/incomplete), impaired uterine healing (partial or complete dehiscence/poor/good), placental abnormalities, and perinatal complications in subsequent pregnancy are may be associated with cesarean myomectomy. In this study, patients who underwent cesarean myomectomy during cesarean section in our institute were analyzed in a retrospective manner. Patients were divided into three groups as those receiving serosal myomectomy, endometrial myomectomy and those who only underwent cesarean section. The groups were compared with respect to the presence of adhesion formation, time to achieve pregnancy (fertility), morphology of the myomectomy scar, presence of uterine rupture and placental abnormalities.

Eligibility Criteria:
Inclusion Criteria:

* Participants should have singleton pregnancy delivered by cesarean section
* Cesarean section technique should include: Transverse hysterotomy to enter the uterine cavity, single layer closure of the uterine wall, non-sutured visceral and parietal peritoneum
* Myomectomy during cesarean section should include: only patients, who have undergone a single myomectomy and have been applied a single layer suture technique with the preservation of the pseudocapsule-for all cesarean myomectomy cases

Exclusion Criteria:

* Patients having history of any malignancy
* Patients with coagulation disorders
* Patients with a history of previous intraabdominal surgery on reproductive organs
* Patients with a history of endometriosis
Utilization of NBi in Assessing Luminal INflammaion in IBD (UNBLIND)

Ulcerative colitis (UC) is a chronic inflammatory condition of unknown aetiology, characterized by a diffuse confluent mucosal inflammation of the colon starting from the rectum with a relapsing and remitting course. Conventional endoscopy was thought to be a reliable parameter of disease activity, but microscopic inflammation can persist despite normal mucosal findings. Histologically detectable inflammation is associated with a greater risk of subsequent relapse. A flare in UC activity is difficult to predict, but a simple, easily measured biological marker of relapse would be important in guiding the most appropriate therapy.

Recent technological advances in fiber optics, light sources, detectors, and molecular biology have stimulated development of numerous optical methods that promise to significantly improve our ability to evaluate human epithelium in vivo. These methods, collectively termed "optical biopsy," are nondestructive in situ assays of mucosal histopathology using light that can provide instantaneous tissue assessment. Narrow band imaging (NBI) is a novel technique that enhances the diagnostic capability of endoscopes in characterising tissues by using filters in a redgreenblue (RGB) sequential illumination system. This results in improved mucosal contrast and detail.

UC always involves the distal colon and activity is usually greatest in rectosigmoid area. This makes evaluation of the rectum and sigmoid an attractive marker in patients with UC. Unlike serum and faecal markers, endoscopic assessment of the mucosa is unlikely to be affected by systemic disease and would be acceptable test for patients and physicians.

We plan to evaluate THE rectosigmoid mucosa in patients with UC by flexible endoscope using both white light and NBI endoscopy. These patients will be followed by for one year or until they relapse, whichever comes first. The aim of our study is to develop endoscopic biomarkers to predict relapse in acute and quiescent UC.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients referred for lower gastrointestinal endoscopy procedure will be recruited.
* Any age (1885 years), gender or ethnic background
* Able and willing to give an informed consent

Exclusion Criteria:

* Patients known to be intolerant to endoscopy.
* Patients with severe lifethreatening comorbidity as judged by the investigator.
* Patients on therapy with anticoagulation that may preclude taking any biopsies
* Pregnant women or breast feeding mothers
* Patient with toxic megacolon
* patients on medications known to cause bowel inflammation.
MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

This study will compare the efficacy and safety of different treatment regimens of oral Bonviva tablets in women with post-menopausal osteoporosis. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.


Eligibility Criteria:
Inclusion Criteria:

* women 55-80 years of age;
* post-menopausal for \>= 5 years;
* ambulatory.

Exclusion Criteria:

* malignant disease diagnosed within the previous 10 years (except basal cell cancer that has been successfully removed);
* breast cancer within the previous 20 years;
* allergy to bisphosphonates;
* previous treatment with an intravenous bisphosphonate at any time;
* previous treatment with an oral bisphosphonate within the last 6 months, \>1 month of treatment within the last year, or \>3 months of treatment within the last 2 years.
Periodic Limb Movement Syndrome in Patients With Cerebral Small Vessel Disease.

Patients from 60 to 75 years old diagnosed with cerebral small vessel disease with no history of symptomatic stroke, brain tumor, traumatic brain injury, seizures and neurodegenerative or mental disorder will undergo overnight leg actigraphy and cardiorespiratory monitoring. Those of them with apnea/hypopnea index under 5 will be enrolled. Brain MRI and cognitive assessment will be performed at baseline and in 1-year follow-up, sleep quality will be assessed at baseline with self-reported questionnaires. Progression of cerebral small vessel disease markers and cognitive dysfunction will be compared between patients with high periodic limb movement index (the number of periodic limb movement ≥ 15 per hour of sleep) and controls (periodic limb movement index \< 15/h).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of a cerebral small vessel disease - assessed by MRI.
* Ability to follow the procedures of the study, fluent Russian language - assessed by self-report.

Exclusion Criteria:

* History of symptomatic stroke, brain tumor or traumatic brain injury - assessed by self-report and clinical history.
* History of severe psychiatric comorbidities other than anxiety and depression, substance use disorder - assessed by self-report and clinical history.
* Significant visual loss (leading to difficulties with performing cognitive tasks) - assessed by self-report and clinical history.
* Presence of dementia - assessed by history and clinical examination.
* Movement disorders (e.g. tremor, dystonia etc.) leading to lower velocity of performing cognitive tasks against the clock - assessed by clinical examination.
* Obstructive sleep apnea syndrome - according to the criteria of International classification of sleep disorders III.
* Restless legs syndrome - according to the criteria of the International restless legs syndrome study group.
* Current intake of neuroleptics, benzodiazepines, selective serotonin reuptake inhibitors - assessed by self-report and clinical history.
Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with hyperphosphatemia not on dialysis.


Eligibility Criteria:
Inclusion Criteria:

* Patients who completed study 1585-CL-0101 or new patients who meet following criteria
* Chronic kidney disease patients (eGFR \< 60 mL/min/1.73 m2)
* Serum phosphorus measurement ≧4.6 mg/dl, \<9.0 mg/dl
* Written informed consent

Exclusion Criteria:

* Patients with gastrointestinal surgery or enterectomy
* Patients with severe cardiac diseases
* Patients with severe constipation or diarrhea
* Patients with a history or complication of malignant tumors
* Patients with uncontrolled hypertension
* Patients treated with parathyroid intervention
Marijuana Effects on Simulated Driving Performance

This study will examine the effects of various strains of marijuana on simulated driving performance; the effects of alcohol administration will also be examined to further understand how marijuana-induced driving changes compare to the effects of alcohol. Secondary outcomes will include physiological effects, subjective- and observer-rated outcomes, and psychomotor performance under the various dose conditions.


Eligibility Criteria:
Inclusion Criteria:

* Healthy, adult participants
* Ages 21-50
* History of marijuana use
* History of alcohol use

Exclusion Criteria:

* Clinically significant medical conditions
* Ongoing/significant drug use outside of marijuana and alcohol use
Tesetaxel as First-line Therapy for Metastatic Breast Cancer

The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer.

Tesetaxel is an orally administered taxane that is in development as first- and second-line treatment for patients with advanced cancers. This study is being undertaken to determine the efficacy and safety of tesetaxel administered as first-line therapy to patients with metastatic breast cancer.


Eligibility Criteria:
Primary Inclusion Criteria:

* Female
* At least 18 years of age
* Histologically or cytologically confirmed adenocarcinoma of the breast
* Stage IV disease
* HER2 status negative
* Measurable disease (revised RECIST; Version 1.1)
* Eastern Cooperative Oncology Group performance status 0 or 1
* Life expectancy of at least 3 months
* Chemotherapy naïve or 1 prior chemotherapy regimen in the adjuvant setting (Prior taxane-based adjuvant therapy allowed provided patient had a disease-free interval of at least 12 months after completing this adjuvant therapy)
* Prior hormonal therapy, aromatase inhibitor therapy, and immunotherapy allowed
* Prior radiotherapy in the adjuvant setting allowed provided that less than 25% of the bone marrow had been irradiated
* Adequate bone marrow, hepatic, and renal function, as specified in the protocol
* At least 4 weeks and recovery from effects of prior surgery, hormonal therapy, aromatase inhibitor therapy, immunotherapy, radiotherapy, or other therapy with an approved or investigational agent
* Ability to swallow an oral solid-dosage form of medication

Primary Exclusion Criteria:

* Known metastasis to the central nervous system
* History of other malignancy within the last 5 years other than curatively treated basal and squamous cell carcinoma of the skin or carcinoma of the cervix in situ
* Significant medical disease other than Stage IV breast cancer
* Presence of neuropathy \> Grade 1 (NCI CTC, Version 4.0)
* History of hypersensitivity to a taxane
* Need to continue any regularly-taken medication that is a potent inhibitor or inducer of the CYP3A pathway or P-glycoprotein activity
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-3001 (NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (NCT06347133). All eligible participants will receive plozasiran administered subcutaneously (SC) approximately every 3 months for 24 months. Participants will be counseled to remain on the specified low-fat diet throughout the study in accordance with local standard of care.


Eligibility Criteria:
Inclusion Criteria:

* Adult males, or nonpregnant (who do not plan to become pregnant), nonlactating adult females, who are able and willing to provide written informed consent prior to the performance of any study-specific procedures
* Completed all required study visits per protocol in the parent study AROAPOC3-3001, AROAPOC3-3003, AROAPOC3-3004 or AROAPOC3-3009
* Female subjects of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 90 days after the End of Study (EOS) or the last dose of plozasiran, whichever is later. Male subjects must agree to use a condom during the study and for at least 90 days after the EOS or last dose of plozasiran whichever is later. Subjects must not donate sperm or eggs during the study and for at least 90 days after the EOS or last dose of plozasiran, whichever is later. Female subjects of childbearing potential on hormonal contraceptives must be stable on medication for \>1 menstrual cycle prior to Day 1.

Exclusion Criteria:

* Subject was permanently discontinued from receiving plozasiran in the parent study due to elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or due to HbA1c elevation that did not respond to antidiabetic regimen
* Subject withdrew consent for continued study treatment in the parent study
* Known hypersensitivity to the active substance or to any of the excipients of plozasiran
* Any new condition or worsening of existing condition or any other situation that in the Investigator's judgment, would make the subject unsuitable for enrollment, could interfere with the subject participating in or completing the study, would make it difficult to comply with protocol requirements, or put the subject at an additional safety risk
* Unwilling to limit alcohol consumption to within moderate limits for the duration of the study.

Note: Other inclusion/exclusion criteria may apply per protocol